5-HT₇ receptor

The 5-HT₇ receptor is a member of the GPCR superfamily of cell surface receptors and is activated by the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT).^[5] The 5-HT₇ receptor is coupled to G_s (stimulates the production of the intracellular signaling molecule cAMP)^[6][7] and is expressed in a variety of human tissues, particularly in the brain, the gastrointestinal tract, and in various blood vessels.^[7] This receptor has been a drug development target for the treatment of several clinical disorders.^[8] The 5-HT₇ receptor is encoded by the HTR7 gene, which in humans is transcribed into 3 different splice variants.^[9]

HTR7
Identifiers
Aliases	HTR7, 5-HT7, 5-HT7 receptor, 5-hydroxytryptamine receptor 7
External IDs	OMIM: 182137 MGI: 99841 HomoloGene: 20244 GeneCards: HTR7
Gene location (Human) Chr. Chromosome 10 (human)^[1] Band 10q23.31 Start 90,740,823 bp^[1] End 90,858,039 bp^[1]
Gene location (Mouse) Chr. Chromosome 19 (mouse)^[2] Band 19 C2|19 30.3 cM Start 35,936,134 bp^[2] End 36,034,907 bp^[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in sperm secondary oocyte testicle gastric mucosa stromal cell of endometrium skeletal muscle tissue amniotic fluid right coronary artery prefrontal cortex monocyte Top expressed in medial dorsal nucleus ventromedial nucleus medial geniculate nucleus mammillary body paraventricular nucleus of hypothalamus utricle lateral geniculate nucleus dorsomedial hypothalamic nucleus lateral hypothalamus globus pallidus More reference expression data BioGPS More reference expression data
Gene ontology Molecular function G protein-coupled receptor activity signal transducer activity neurotransmitter receptor activity G protein-coupled serotonin receptor activity serotonin binding protein binding Cellular component integral component of membrane plasma membrane integral component of plasma membrane membrane dendrite Biological process smooth muscle contraction G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger circadian rhythm blood circulation vasoconstriction signal transduction chemical synaptic transmission adenylate cyclase-inhibiting serotonin receptor signaling pathway G protein-coupled receptor signaling pathway G protein-coupled serotonin receptor signaling pathway Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 3363 15566 Ensembl ENSG00000148680 ENSMUSG00000024798 UniProt P34969 P32304 RefSeq (mRNA) NM_019860 NM_000872 NM_019859 NM_008315 NM_001347442 NM_001360297 NM_001360298 NM_001360300 NM_001360318 RefSeq (protein) NP_000863 NP_062873 NP_062874 NP_001334371 NP_032341 NP_001347226 NP_001347227 NP_001347229 NP_001347247 Location (UCSC) Chr 10: 90.74 – 90.86 Mb Chr 19: 35.94 – 36.03 Mb PubMed search ^[3] ^[4]
Wikidata
View/Edit Human View/Edit Mouse

Function

When the 5-HT₇ receptor is activated by serotonin, it sets off a cascade of events starting with release of the stimulatory G protein G_s from the GPCR complex. G_s in turn activates adenylate cyclase which increases intracellular levels of the second messenger cAMP.

The 5-HT₇ receptor plays a role in smooth muscle relaxation within the vasculature and in the gastrointestinal tract.^[5] The highest 5-HT₇ receptor densities are in the thalamus and hypothalamus, and it is present at higher densities also in the hippocampus and cortex. The 5-HT₇ receptor is involved in thermoregulation, circadian rhythm, learning and memory, and sleep. Peripheral 5-HT₇ receptors are localized in enteric nerves; high levels of 5-HT₇ receptor-expressing mucosal nerve fibers were observed in the colon of patients with irritable bowel syndrome. An essential role of 5-HT₇ receptor in intestinal hyperalgesia was demonstrated in mouse models with visceral hypersensitivity, of which a novel 5-HT₇ receptor antagonist administered perorally reduced intestinal pain levels.^[10] It is also speculated that this receptor may be involved in mood regulation, suggesting that it may be a useful target in the treatment of depression.^[11][12]

Variants

Three splice variants have been identified in humans (designated h5-HT_7(a), h5-HT_7(b), and h5-HT_7(d)), which encode receptors that differ in their carboxy terminals.^[9] The h5-HT_7(a) is the full length receptor (445 amino acids),^[7] while the h5-HT_7(b) is truncated at amino acid 432 due to alternative splice donor site. The h5-HT_7(d) is a distinct isoform of the receptor: the retention of an exon cassette in the region encoding the carboxyl terminal results a 479-amino acid receptor with a c-terminus markedly different from the h5-HT_7(a). A 5-HT_7(c) splice variant is detectable in rat tissue but is not expressed in humans. Conversely, rats do not express a splice variant homologous to the h5-HT_7(d), as the rat 5-HT₇ gene lacks the exon necessary to encode this isoform.^[9] Drug binding affinities are similar across the three human splice variants;^[13] however, inverse agonist efficacies appear to differ between the splice variants.^[14]

Discovery

In 1983, evidence for a 5-HT₁-like receptor was first found.^[15] Ten years later, 5-HT₇ receptor was cloned and characterized.^[7] It has since become clear that the receptor described in 1983 is 5-HT₇.^[16]

Ligands

Numerous orthosteric ligands of moderate to high affinity are known. Signaling biased ligands were discovered and developed in 2018.^[17]

Agonists

Agonists mimic the effects of the endogenous ligand, which is serotonin at the 5-HT₇ receptor (↑cAMP).

• 5-Carboxamidotryptamine (5-CT)
• 5-methoxytryptamine (5-MT, 5-MeOT)
• 8-OH-DPAT (mixed 5-HT_1A/5-HT₇ agonist)^[18]
• Aripiprazole (weak partial agonist)^[19]
• AS-19
• E-55888^[20]
• E-57431^[21]
• LP-12 (4-(2-Diphenyl)-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide)
• LP-44 (4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide)
• LP-211
• MSD-5a^[22]
• N_ω-Methylserotonin^[23]
• N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides (can function as either an agonist or antagonist depending on side chain substitution)^[24][25]
• N,N-Dimethyltryptamine
• AGH-107 (water-soluble, brain penetrating full agonist) ^[26]
• AH-494 (3-(1-ethyl-1H-imidazol-5-yl)-1H-indole-5-carboxamide) ^[27]
• AGH-192 (orally bioavailable, water-soluble, brain penetrating full agonist)^[28]

Antagonists

Neutral antagonists (also known as silent antagonists) bind the receptor and have no intrinsic activity but will block the activity of agonists or inverse agonists. Inverse agonists inhibit the constitutive activity of the receptor, producing functional effects opposite to those of agonists (at the 5-HT₇ receptor: ↓cAMP).^[29][30] Neutral antagonists and inverse agonists are typically referred to collectively as "antagonists" and, in the case of the 5-HT₇ receptor, differentiation between neutral antagonists and inverse agonists is problematic due to differing levels of inverse agonist efficacy between receptor splice variants. For instance, mesulergine and metergoline are reported to be neutral antagonists at the h5-HT_7(a) and h5-HT_7(d) receptor isoforms but these drugs display marked inverse agonist effects at the h5-HT_7(b) splice variant.^[14]

• 3-{4-[4-(4-chlorophenyl)-piperazin-1-yl]-butyl}-3-ethyl-6-fluoro-1,3-dihydro-2H-indol-2-one^[31]
• Amisulpride^[32]
• Amitriptyline
• Amoxapine
• Brexpiprazole
• Clomipramine
• Clozapine
• CYY1005 (a highly selective, orally active 5-HT7 antagonist) ^[10]
• DR-4485
• EGIS-12233 (mixed 5-HT₆/5-HT₇ antagonist)
• AVN-101 (mixed 5-HT₆/5-HT₇ antagonist) ^[33]
• Fluphenazine
• Fluperlapine
• ICI 169,369
• Imipramine
• JNJ-18038683
• Ketanserin
• Loxapine
• Lurasidone
• LY-215,840
• Maprotiline
• Mesulergine
• Methysergide
• Mianserin
• Olanzapine
• Pimozide
• RA-7 (1-(2-diphenyl)piperazine)^[34]
• Ritanserin
• SB-258,719^[35][36][37]
• SB-258741^[37]
• SB-269970 (highly 5-HT₇ selective)^[38]
• SB-656104-A^[39]
• SB-691673^[35]
• Sertindole
• Spiperone
• Tenilapine
• TFMPP
• Vortioxetine
• Trifluoperazine
• Ziprasidone
• Zotepine

Inactivating antagonists

Inactivating antagonists are non-competitive antagonists that render the receptor persistently insensitive to agonist, which resembles receptor desensitization. Inactivation of the 5-HT₇ receptor, however, does not arise from the classically described mechanisms of receptor desensitization via receptor phosphorylation, beta-arrestin recruitment, and receptor internalization.^[40] Inactivating antagonists all likely interact with the 5-HT₇ receptor in an irreversible/pseudo-irreversible manner, as is the case with [³H]risperidone.^[41][42]

• Bromocriptine^[42]
• Lisuride^[42]
• Metergoline^[42]
• Methiothepin^[41]
• Paliperidone^[41]
• Risperidone^[41]

See also

• 5-HT receptor
• 5-HT₁ receptor
• 5-HT₂ receptor
• 5-HT₃ receptor
• 5-HT₄ receptor
• 5-HT₅ receptor
• 5-HT₆ receptor

References

1. GRCh38: Ensembl release 89: ENSG00000148680 – Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000024798 – Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Vanhoenacker P, Haegeman G, Leysen JE (February 2000). "5-HT7 receptors: current knowledge and future prospects". Trends in Pharmacological Sciences. 21 (2): 70–7. doi:10.1016/S0165-6147(99)01432-7. PMID 10664612.
6. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM, Schwartz JC (September 1993). "Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation". Proceedings of the National Academy of Sciences of the United States of America. 90 (18): 8547–51. Bibcode:1993PNAS...90.8547R. doi:10.1073/pnas.90.18.8547. PMC 47394. PMID 8397408.
7. Bard JA, Zgombick J, Adham N, Vaysse P, Branchek TA, Weinshank RL (November 1993). "Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase". The Journal of Biological Chemistry. 268 (31): 23422–6. doi:10.1016/S0021-9258(19)49479-9. PMID 8226867.
8. Mnie-Filali O, Lambás-Señas L, Zimmer L, Haddjeri N (December 2007). "5-HT7 receptor antagonists as a new class of antidepressants". Drug News & Perspectives. 20 (10): 613–8. doi:10.1358/dnp.2007.20.10.1181354. PMID 18301795.
9. Heidmann DE, Metcalf MA, Kohen R, Hamblin MW (April 1997). "Four 5-hydroxytryptamine7 (5-HT7) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron-exon organization". Journal of Neurochemistry. 68 (4): 1372–81. doi:10.1046/j.1471-4159.1997.68041372.x. PMID 9084407. S2CID 25951920.
10. Chang WY, Yang YT, She MP, Tu CH, Lee TC, Wu MS, Sun CH, Hsin LW, Yu LC (2022). "5-HT 7 receptor-dependent intestinal neurite outgrowth contributes to visceral hypersensitivity in irritable bowel syndrome". Laboratory Investigation. 102 (9): 1023–1037. doi:10.1038/s41374-022-00800-z. PMC 9420680. PMID 35585132.
11. Hedlund PB, Sutcliffe JG (September 2004). "Functional, molecular and pharmacological advances in 5-HT7 receptor research". Trends in Pharmacological Sciences. 25 (9): 481–6. doi:10.1016/j.tips.2004.07.002. PMID 15559250.
12. Naumenko VS, Popova NK, Lacivita E, Leopoldo M, Ponimaskin EG (July 2014). "Interplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disorders". CNS Neuroscience & Therapeutics. 20 (7): 582–90. doi:10.1111/cns.12247. PMC 6493079. PMID 24935787.
13. Krobert KA, Bach T, Syversveen T, Kvingedal AM, Levy FO (June 2001). "The cloned human 5-HT7 receptor splice variants: a comparative characterization of their pharmacology, function and distribution". Naunyn-Schmiedeberg's Archives of Pharmacology. 363 (6): 620–32. doi:10.1007/s002100000369. PMID 11414657. S2CID 21899516.
14. Krobert KA, Levy FO (March 2002). "The human 5-HT7 serotonin receptor splice variants: constitutive activity and inverse agonist effects". British Journal of Pharmacology. 135 (6): 1563–71. doi:10.1038/sj.bjp.0704588. PMC 1573253. PMID 11906971.
15. Feniuk W, Humphrey PP, Watts AD (December 1983). "5-Hydroxytryptamine-induced relaxation of isolated mammalian smooth muscle". European Journal of Pharmacology. 96 (1–2): 71–8. doi:10.1016/0014-2999(83)90530-7. PMID 6662198.
16. Hoyer D, Hannon JP, Martin GR (April 2002). "Molecular, pharmacological and functional diversity of 5-HT receptors". Pharmacology Biochemistry and Behavior. 71 (4): 533–54. doi:10.1016/S0091-3057(01)00746-8. PMID 11888546. S2CID 25543069.
17. Kim Y, Kim H, Lee J, Lee JK, Min SJ, Seong J, Rhim H, Tae J, Lee HJ, Choo H (August 2018). "Discovery of β-Arrestin Biased Ligands of 5-HT7R". J. Med. Chem. 61 (16): 7218–7233. doi:10.1021/acs.jmedchem.8b00642. PMID 30028132. S2CID 51700960.
18. Sprouse J, Reynolds L, Li X, Braselton J, Schmidt A (January 2004). "8-OH-DPAT as a 5-HT7 agonist: phase shifts of the circadian biological clock through increases in cAMP production". Neuropharmacology. 46 (1): 52–62. doi:10.1016/j.neuropharm.2003.08.007. PMID 14654097. S2CID 41623573.
19. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A Novel Atypical Antipsychotic Drug With a Uniquely Robust Pharmacology. CNS Drug Reviews [Internet]. 2004 [cited 2013 Aug 4];10(4):317–36. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1527-3458.2004.tb00030.x/pdf
20. Brenchat A, Ejarque M, Zamanillo D, Vela JM, Romero L (August 2011). "Potentiation of morphine analgesia by adjuvant activation of 5-HT7 receptors". Journal of Pharmacological Sciences. 116 (4): 388–91. doi:10.1254/jphs.11039sc. PMID 21778664.
21. Brenchat A, Nadal X, Romero L, Ovalle S, Muro A, Sánchez-Arroyos R, Portillo-Salido E, Pujol M, Montero A, Codony X, Burgueño J, Zamanillo D, Hamon M, Maldonado R, Vela JM (June 2010). "Pharmacological activation of 5-HT7 receptors reduces nerve injury-induced mechanical and thermal hypersensitivity". Pain. 149 (3): 483–94. doi:10.1016/j.pain.2010.03.007. PMID 20399562. S2CID 16613426.
22. Brenchat A, Romero L, García M, Pujol M, Burgueño J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM (February 2009). "5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice". Pain. 141 (3): 239–47. doi:10.1016/j.pain.2008.11.009. PMID 19118950. S2CID 27144262.
23. Powell SL, Gödecke T, Nikolic D, Chen SN, Ahn S, Dietz B, Farnsworth NR, van Breemen RB, Lankin DC, Pauli GF, Bolton JL (December 2008). "In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent". Journal of Agricultural and Food Chemistry. 56 (24): 11718–26. doi:10.1021/jf803298z. PMC 3684073. PMID 19049296.
24. Leopoldo M, Lacivita E, Contino M, Colabufo NA, Berardi F, Perrone R (August 2007). "Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2". Journal of Medicinal Chemistry. 50 (17): 4214–21. doi:10.1021/jm070487n. PMID 17649988.
25. Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Niso M, Perrone R, Tortorella V (December 2004). "Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents". Journal of Medicinal Chemistry. 47 (26): 6616–24. doi:10.1021/jm049702f. PMID 15588097.
26. Hogendorf AS, Hogendorf A, Kurczab R, Satała G, Lenda T, Walczak M, Latacz G, Handzlik J, Kieć-Kononowicz K, Wierońska JM, Woźniak M, Cieślik P, Bugno R, Staroń J, Bojarski AJ (May 2017). "Low-basicity 5-HT7 Receptor Agonists Synthesized Using the van Leusen Multicomponent Protocol". Scientific Reports. 7 (1444): 1444. Bibcode:2017NatSR...7.1444H. doi:10.1038/s41598-017-00822-4. PMC 5431432. PMID 28473721.
27. Latacz G, Hogendorf AS, Hogendorf A, Lubelska A, Wierońska JM, Woźniak M, Cieślik P, Kieć-Kononowicz K, Handzlik J, Bojarski AJ (September 2018). "Search for a 5-CT alternative. In vitro and in vivo evaluation of novel pharmacological tools: 3-(1-alkyl-1H-imidazol-5-yl)-1H-indole-5-carboxamides, low-basicity 5-HT7 receptor agonists". MedChemComm. 9 (11): 1882–1890. doi:10.1039/c8md00313k. PMC 6256855. PMID 30568756.
28. Hogendorf AS, Hogendorf A, Popiolek-Barczyk K, Ciechanowska A, Mika J, Satała G, Walczak M, Latacz G, Handzlik J, Kieć-Kononowicz K, Ponimaskin E, Schade S, Zeug A, Bijata M, Kubicki M, Kurczab R, Lenda T, Staroń J, Kurczab R, Satała G, Lenda T, Walczak M, Latacz G, Handzlik J, Kieć-Kononowicz K, Wierońska JM, Woźniak M, Cieślik P, Bugno R, Staroń J, Bugno R, Duszyńska B, Pilarski B, Bojarski AJ (2019). "Fluorinated indole-imidazole conjugates: Selective orally bioavailable 5-HT7 receptor low-basicity agonists, potential neuropathic painkillers". European Journal of Medicinal Chemistry. 170: 261–275. doi:10.1016/j.ejmech.2019.03.017. PMID 30904783. S2CID 85498356.
29. Pittalà V, Salerno L, Modica M, Siracusa MA, Romeo G (September 2007). "5-HT7 receptor ligands: recent developments and potential therapeutic applications". Mini Reviews in Medicinal Chemistry. 7 (9): 945–60. doi:10.2174/138955707781662663. PMID 17897083.
30. Leopoldo M (March 2004). "Serotonin(7) receptors (5-HT(7)Rs) and their ligands". Current Medicinal Chemistry. 11 (5): 629–61. doi:10.2174/0929867043455828. PMID 15032609.
31. Volk B, Barkóczy J, Hegedus E, Udvari S, Gacsályi I, Mezei T, Pallagi K, Kompagne H, Lévay G, Egyed A, Hársing LG, Spedding M, Simig G (April 2008). "(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonists". Journal of Medicinal Chemistry. 51 (8): 2522–32. doi:10.1021/jm070279v. PMID 18361484.
32. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL (July 2009). "Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo". Psychopharmacology. 205 (1): 119–28. doi:10.1007/s00213-009-1521-8. PMC 2821721. PMID 19337725.
33. Ivachtchenko AV, Lavrovsky Y, Okun I (2016). "AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders". J. Alzheimer's Dis. 53 (2): 583–620. doi:10.3233/JAD-151146. PMC 4969713. PMID 27232215.
34. Lacivita E, Patarnello D, Stroth N, Caroli A, Niso M, Contino M, De Giorgio P, Di Pilato P, Colabufo NA, Berardi F, Perrone R, Svenningsson P, Hedlund PB, Leopoldo M (2012). "Investigations on the 1-(2-Biphenyl)piperazine Motif: Identification of New Potent and Selective Ligands for the Serotonin7 (5-HT7) Receptor with Agonist or Antagonist Action in Vitro or ex Vivo". Journal of Medicinal Chemistry. 55 (14): 6375–6380. doi:10.1021/jm3003679. PMID 22738316.
35. Romero G, Pujol M, Pauwels PJ (October 2006). "Reanalysis of constitutively active rat and human 5-HT7(a) receptors in HEK-293F cells demonstrates lack of silent properties for reported neutral antagonists". Naunyn-Schmiedeberg's Archives of Pharmacology. 374 (1): 31–9. doi:10.1007/s00210-006-0093-y. PMID 16967291. S2CID 25203956.
36. Forbes IT, Dabbs S, Duckworth DM, Jennings AJ, King FD, Lovell PJ, Brown AM, Collin L, Hagan JJ, Middlemiss DN, Riley GJ, Thomas DR, Upton N (February 1998). "(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist". Journal of Medicinal Chemistry. 41 (5): 655–7. doi:10.1021/jm970519e. PMID 9513592.
37. Mahé C, Loetscher E, Feuerbach D, Müller W, Seiler MP, Schoeffter P (July 2004). "Differential inverse agonist efficacies of SB-258719, SB-258741 and SB-269970 at human recombinant serotonin 5-HT7 receptors". European Journal of Pharmacology. 495 (2–3): 97–102. doi:10.1016/j.ejphar.2004.05.033. PMID 15249157.
38. Lovell PJ, Bromidge SM, Dabbs S, Duckworth DM, Forbes IT, Jennings AJ, King FD, Middlemiss DN, Rahman SK, Saunders DV, Collin LL, Hagan JJ, Riley GJ, Thomas DR (February 2000). "A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970)". Journal of Medicinal Chemistry. 43 (3): 342–5. doi:10.1021/jm991151j. PMID 10669560.
39. Forbes IT, Douglas S, Gribble AD, Ife RJ, Lightfoot AP, Garner AE, Riley GJ, Jeffrey P, Stevens AJ, Stean TO, Thomas DR (November 2002). "SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties". Bioorganic & Medicinal Chemistry Letters. 12 (22): 3341–4. doi:10.1016/S0960-894X(02)00690-X. PMID 12392747.
40. Zhang J, Ferguson SS, Barak LS, Aber MJ, Giros B, Lefkowitz RJ, Caron MG (1997). "Molecular mechanisms of G protein-coupled receptor signaling: role of G protein-coupled receptor kinases and arrestins in receptor desensitization and resensitization". Receptors & Channels. 5 (3–4): 193–9. PMID 9606723.
41. Smith C, Rahman T, Toohey N, Mazurkiewicz J, Herrick-Davis K, Teitler M (October 2006). "Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor". Molecular Pharmacology. 70 (4): 1264–70. doi:10.1124/mol.106.024612. PMID 16870886. S2CID 1678887.
42. Knight JA, Smith C, Toohey N, Klein MT, Teitler M (February 2009). "Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists". Molecular Pharmacology. 75 (2): 374–80. doi:10.1124/mol.108.052084. PMC 2671286. PMID 18996971.

External links

• "5-HT₇". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology.
• Human HTR7 genome location and HTR7 gene details page in the UCSC Genome Browser.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.